Black Rock Inc. Moon Lake Immunotherapeutics Transaction History

Black Rock Inc.

$4.35 Trillion
Q2 2024

A detailed history of Black Rock Inc. transactions in Moon Lake Immunotherapeutics stock. As of the latest transaction made, Black Rock Inc. holds 392,024 shares of MLTX stock, worth $20.1 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

392,024

Previous 408,280 3.98%

Holding current value

$20.1 Million

Previous $20.5 Million 15.95%

% of portfolio

0.0%

Previous 0.0%

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 13, 2024	SELL	$38.43 - $48.6 $624,718 - $790,041	-16,256 Reduced 3.98%	392,024 $17.2 Million
Q1 2024 May 10, 2024	BUY	$43.78 - $63.86 $1.16 Million - $1.7 Million	26,554 Added 6.96%	408,280 $20.5 Million
Q4 2023 Feb 13, 2024	SELL	$36.35 - $63.02 $13.3 Million - $23.1 Million	-367,152 Reduced 49.03%	381,726 $23.1 Million
Q3 2023 Nov 13, 2023	BUY	$48.35 - $61.26 $4.42 Million - $5.6 Million	91,344 Added 13.89%	748,878 $42.7 Million
Q2 2023 Aug 11, 2023	BUY	$19.01 - $51.79 $10.3 Million - $28.1 Million	542,604 Added 472.12%	657,534 $33.5 Million
Q1 2023 May 12, 2023	SELL	$11.03 - $23.7 $6.91 Million - $14.9 Million	-626,828 Reduced 84.51%	114,930 $2.46 Million
Q4 2022 Feb 13, 2023	SELL	$7.05 - $10.5 $521 - $777	-74 Reduced 0.01%	741,758 $7.79 Million
Q3 2022 Nov 14, 2022	SELL	$5.25 - $9.27 $388 - $685	-74 Reduced 0.01%	741,832 $5.76 Million
Q2 2022 Aug 12, 2022	BUY	$4.69 - $13.25 $3.48 Million - $9.83 Million	741,906 New	741,906 $3.9 Million

Others Institutions Holding MLTX

# of Institutions

124

Shares Held

58.2M

Call Options Held

52.2K

Put Options Held

38K

View Full List

About MoonLake Immunotherapeutics

Ticker MLTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 36,925,600
Market Cap $1.89B
Description
MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies. It is developing Sonelokimab, a novel investigational Nanobody therapy for the treatment of inflammation. The company is involved in conducting Phase II trials for hidradenitis suppurativa, psoriatic arthritis, ankylosing spondylitis, or rad...

More about MLTX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Black Rock Inc., based on Form 13F filings with the SEC.

News

Stay updated on Black Rock Inc. with notifications on news.

Account